Bioanalytical method development, in-vivo pharmacokinetic evaluation, ex-vivo platelet aggregation inhibition activity of a novel solid dispersion formulation of ticagrelor
In conclusion, we have successfully developed a validated analytical method for estimating Ticagrelor plasma concentration. Additionally, our study successfully enhanced Ticagrelor's oral bioavailability, and the developed formulation has more significant inhibition of ADP-induced platelet aggregation relative to the marketed formulation, indicating its substantial therapeutic potential.
Authors
- Simrata Bedi
- Mohammad Ahmed Khan (ORCID: https://orcid.org/0000-0002-7401-3299)
- Madaswamy S. Muthu (ORCID: https://orcid.org/0000-0001-5805-7921)
- Abhishesh Kumar Mehata (ORCID: https://orcid.org/0000-0003-1392-5849)
- Ketan Hatware (ORCID: https://orcid.org/0000-0001-6504-1354)
- Uma Bhandari (ORCID: https://orcid.org/0000-0003-2277-9142)
- Datta Maroti Pawde
- Abhishek Kumar Srivastava (ORCID: https://orcid.org/0000-0001-5345-6405)
Institutions
- Jamia Hamdard (IN)
- Narsee Monjee Institute of Management Studies (IN)
- MIT World Peace University (IN)
- Sun Pharma Advanced Research (India) (IN)
- Indian Institute of Technology BHU (IN)
- Banaras Hindu University (IN)
Publication Details
- Journal
- Frontiers in Medical Technology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fmedt.2025.1499189
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39